LA MINOCICLINA, NUEVOS USOS PARA UN VIEJO ANTIBIÓTICO, ACTUALIZACIÓN !!
THE MINOCYCLINE, NEW USES FOR AN OLD ANTIBIOTIC, UPDATE !!
==================
Hola de nuevo amigos DERMAGICOS, hoy con este interesante
tema sobre la
MINOCICLINA,
NUEVOS USOS PARA UN VIEJO ANTIBIÓTICO.
La MINOCICLINA pertenece a la
segunda generación de ciclinas, miembro de las
tetraciclinas. Se sintetizó en 1967 por el
laboratorio Lederle, y se comercializó en 1972; descubierta por los
investigadores
James Boothe y Michael Martell Jr.
La Minociclina tiene una actividad anti infecciosa con un
espectro similar al de otras ciclinas, especialmente contra
Chlamydias,
Treponema
y
Proprionibacterium acnes.
Un antiguo antibiótico que a través del tiempo se le han
descubierto propiedades beneficiosas en algunas enfermedades que
tal vez nunca imaginaste.
Esta publicación fue lanzada a la red a mediados del año 1999, bajo el titulo de LA MINOCICLINA, LO BUENO LO MALO Y LO FEO. A Esta medicina se le han descubierto propiedades beneficiosas en enfermedades para las cuales no fue creada ni lanzada el mercado, tal es el caso de la LEPRA, donde se describe su efecto BACTERICIDA sobre el Mycobacterium Leprae.
Esta publicación fue lanzada a la red a mediados del año 1999, bajo el titulo de LA MINOCICLINA, LO BUENO LO MALO Y LO FEO. A Esta medicina se le han descubierto propiedades beneficiosas en enfermedades para las cuales no fue creada ni lanzada el mercado, tal es el caso de la LEPRA, donde se describe su efecto BACTERICIDA sobre el Mycobacterium Leprae.
Principalmente esta droga ha sido, fue y es usada para e
tratamiento del acne. Pero poco a poco se fue extendiendo el rango
de sus uso.
Hoy se las traigo actualizada, para llamar la atención de todos
los lectores, en el sentido de que a esta ¨vieja¨ medicina, hoy
dia se le describen propiedades antiinflamatorias y
neuro-protectoras en enfermedades neurológicas, entre las que
destacan la
ENFERMEDAD DE ALZHEIMER y LA ESQUIZOFRENIA. (referencias 31 -53)
LO BUENO:
==========
Este medicamento popular tiene efectos beneficiosos sobre enfermedades como:
1.) LEPRA (MYCOBACTERIUM LEPRAE)
2.) ESCLERODERMIA.
3.) PÉNFIGO.
4.) PIODERMA GANGRENOSO.
5.) PENFIGOIDE CICATRICIAL
6.) PAPILOMATOSIS RETICULADA.
7.) ENFERMEDAD DE LYME (ERITEMA MIGRANS)
8.) ACNE
9.) CHLAMYDIA
10.) TREPONEMA
11.) MYCOBATERIUM KANSAII
12.) NOCARDIOSIS PULMONAR.
12.) BLASTOMICOSIS.
13.) ARTRITIS REUMATOIDE.
14.) QUISTES HEPÁTICOS y OTROS.
Pero lo más interesante del tema sobre la MINOCICLINA es su uso en desórdenes necrológicos, descubriéndose efectos NEUROPROTECTORES. Se ha descubierto que la MINOCICLINA tiene efectos beneficiosos sobre:
LO BUENO:
==========
Este medicamento popular tiene efectos beneficiosos sobre enfermedades como:
1.) LEPRA (MYCOBACTERIUM LEPRAE)
2.) ESCLERODERMIA.
3.) PÉNFIGO.
4.) PIODERMA GANGRENOSO.
5.) PENFIGOIDE CICATRICIAL
6.) PAPILOMATOSIS RETICULADA.
7.) ENFERMEDAD DE LYME (ERITEMA MIGRANS)
8.) ACNE
9.) CHLAMYDIA
10.) TREPONEMA
11.) MYCOBATERIUM KANSAII
12.) NOCARDIOSIS PULMONAR.
12.) BLASTOMICOSIS.
13.) ARTRITIS REUMATOIDE.
14.) QUISTES HEPÁTICOS y OTROS.
Pero lo más interesante del tema sobre la MINOCICLINA es su uso en desórdenes necrológicos, descubriéndose efectos NEUROPROTECTORES. Se ha descubierto que la MINOCICLINA tiene efectos beneficiosos sobre:
- La INFLAMACIÓN.
- La activación microglial.
- La
muerte celular apoptótica
en el SISTEMA NERVIOSO CENTRAL (SNC), y se utiliza en enfermedades
tales como:
1.) ENFERMEDAD DE ALZHEIMER.
2.) ENFERMEDAD DE PARKINSON
3.) ESCLEROSIS MÚLTIPLE.
4.) TRASTORNOS BIPOLARES.
5.) ESQUIZOFRENIA.
6.) ENCEFALOMIELITIS AUTO-INMUNE.
¿Quién iba a pensar que este viejo antibiótico que tiene más de 40 años en el mercado, hoy está siendo utilizado en enfermedades como el ALZHEIMER y la ESQUIZOFRENIA.
La gran pregunta es ? podría utilizarse la minociclina para provocar NEUROPROTECCION, o mejorar el estado inflamatorio en estos desordenes neurológicos, a dosis minima para evitar efectos secundarios.? La única manera de saberlo es mediante mas estudios al respecto.
También seria interesante conocer que nivel de NEUROPROTECCION desarrollaron aquellos pacientes que tomaron minociclina a largo plazo para el tratamiento del acne.
LO MALO:
=========
Como todos los medicamentos la MINOCICLINA tiene sus efectos adversos, entre ellos destacan:
1.) ENFERMEDAD DE ALZHEIMER.
2.) ENFERMEDAD DE PARKINSON
3.) ESCLEROSIS MÚLTIPLE.
4.) TRASTORNOS BIPOLARES.
5.) ESQUIZOFRENIA.
6.) ENCEFALOMIELITIS AUTO-INMUNE.
¿Quién iba a pensar que este viejo antibiótico que tiene más de 40 años en el mercado, hoy está siendo utilizado en enfermedades como el ALZHEIMER y la ESQUIZOFRENIA.
La gran pregunta es ? podría utilizarse la minociclina para provocar NEUROPROTECCION, o mejorar el estado inflamatorio en estos desordenes neurológicos, a dosis minima para evitar efectos secundarios.? La única manera de saberlo es mediante mas estudios al respecto.
También seria interesante conocer que nivel de NEUROPROTECCION desarrollaron aquellos pacientes que tomaron minociclina a largo plazo para el tratamiento del acne.
LO MALO:
=========
Como todos los medicamentos la MINOCICLINA tiene sus efectos adversos, entre ellos destacan:
1.)
HEPATITIS AUTOIMUNE.
4.)
LUPUS ERITEMATOSO.
4.) REACCIONES DE HIPERSENSIBILIDAD.
5.)
ENFERMEDAD DEL SUERO-LIKE. (urticaria, fiebre, linfadenopatias, y dolores
articulares).
6.)
PERDIDA DE POTASIO
(glóbulos rojos).
LO FEO:
=========
=========
1.)
HIPERPIGMENTACIÓN: es uno de los efectos secundarios mas frecuentes del uso de la
MINOCICLINA, hecho que se ha reportado en, encías, huesos, cara,
tiroides.
2.)
INDUCCIÓN DE AUTO-ANTICUERPOS: (caso de psoriasis)
3.) OSTEOMA CUTIS HIPERPIGMENTADO: (post tratamiento
de acne).
4.) HIPERPLASIA NODULAR: (tiroides).
El hecho mas resaltante de esta publicación, es que se descubren propiedades de un medicamento, YA OLVIDADO, en enfermedades DIFÍCILES de tratar como LEPRA, ALZHEIMER y ESQUIZOFRENIA.
El TÍPICO EJEMPLO de lo presentado, ocurrió 40 años después con
la
IVERMECTINA, y la HIDROXICLOROQUINA, medicamentos ANTIPARASITARIOS, a los cuales se les
descubrió su efecto ANTIVIRAL, específicamente contra el
VIRUS del SARS- COV-2.
De como un medicamento SINTETIZADO para una enfermedad
especifica, y luego se le descubren otros efectos POSITIVOS, en
otras enfermedades, ejemplos:
1.) SILDENAFIL (VIAGRA):
Estudiado y probado como HIPOTENSOR, resulto un EXITO en la
disfunción eréctil y luego su MOLÉCULA fue mejorada (VARDENAFIL Y
TADALAFIL).
2.) MINOXIDIL: también estudiado como HIPOTENSOR, los pacientes de ensayo
presentaron una HIPERVELLOSIDAD TOTAL en la cara: así nació
su uso para la caída del CABELLO o ALOPECIA.
3.) FINASTERIDE:
inventado para el tratamiento de la HIPERPLASIA PROSTATICA BENIGNA
(HPB); se le descubrió que evitaba la caída del cabello: así nació
la PROPECIA, y en noviembre 2024, salio al mercado la version
TÓPICA, bajo el nombre de
FINASTOPIC
del laboratorio ISDIN. (España).
4.) IVERMECTINA:
Inventado en los años 70 como ANTIPARASITARIO, y ganador del
premio NOBEL en el año 2015. Posteriormente en 2020 se comienza a
usar en el tratamiento del COVID 19.
"LA FDA NO LA APROBÓ, pero ya hay estudios que demuestran que SI ES EFECTIVO, pero a las BIG PHARMA no les conviene que esto se sepa; pero para evitar conflictos de interés: HOY DIA NO ESTA APROBADA para su uso contra el SARS-COV-2."
5. ) LA
TALIDOMIDA:
Lanzada al mercado en 1957 como medicamento para las nauseas y
ansiedad en las mujeres EMBARAZADAS, con grandes efectos
TERATOGÉNICOS (se sabia ?). Provoco una generación de niños
"MUTILADOS" por un efecto llamado FOCOMELIA, descontinuada en
1961. Pero en 1998 volvió a ser lanzada al mercado por sus efectos
beneficiosos en:
- La LEPRA (Reacción de Reversion).
- Varios tipos de CANCER.
- ERITEMA NODOSO.
- MIELOMA MULTIPLE.
- ENFERMEDAD DE BEHCET,.
- ESTOMATITIS AFTOSA RECURRENTE, y otras.
Por ello, esta publicación (hoy actualizada), cuando la
lance a la internet bajo el nombre ya mencionado:
LA MINOCICLINA, LO BUENO, LO MALO Y LO FEO, fue un éxito total, al punto que fue publicada en la REVISTA DE
DERMATOLOGÍA DE CHILE..., hoy dia, este antibiótico sigue
mostrando NUEVAS propiedades positivas.
Hoy dia la MINOCICLINA esta aprobada por la FDA para el tratamiento del acne, pero NO para el tratamiento de condiciones NEUROLOGICAS, en estos casos se utilizan como medicamentos "reutilizados".
Hoy dia la MINOCICLINA esta aprobada por la FDA para el tratamiento del acne, pero NO para el tratamiento de condiciones NEUROLOGICAS, en estos casos se utilizan como medicamentos "reutilizados".
La publicación original de este articulo la encuentras en este
enlace:
LA MINOCICLINA, LO BUENO LO MALO Y LO FEO.
Los hechos en estas 81 referencias !!
Saludos a todos !!!
Dr. Jose Lapenta.
Dr. Jose M. Lapenta.
EDITORIAL ENGLISH
==================
Today, MINOCYCLINE is FDA-approved for the treatment of acne, but NOT for the treatment of NEUROLOGICAL conditions; in these cases, it is used as a "repurposed" drug.
====================================================================== REFERENCIAS BIBLIOGRÁFICAS / BIBLIOGRAPHICAL REFERENCES
====================================================================== ====================================================================== ()()()()()()()()()()()()LO BUENO () THE GOOD ()()()()()()()()()()()()()()
=========================================================================
A.- Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis (2023).
==================
Hello again DERMAGIC friends, today with this interesting topic on
the
MINOCYCLINE, NEW USES FOR AN OLD ANTIBIOTIC.
MINOCYCLINE belongs to the second generation of cyclins, a member of
the tetracycline group.
It was synthesized in 1967 by the Lederle laboratory
and marketed in 1972; it was discovered by researchers
James Boothe and Michael Martell Jr.
MINOCYCLINE has an antiinfectious activity with a spectrum similar to
that of other cyclines, notably against Chlamydias,
Treponema and Proprionibacterium acnes, An old
antibiotic that through time has been discovered beneficial
properties in some diseases that perhaps you never imagined.
This publication was launched online in mid-1999, under the title: THE MINOCYCLINE, THE GOOD THE BAD AND THE UGLY. This medicine has been discovered beneficial properties in diseases for which was not created or launched to the market, such is the case of LEPROSY, which describes its BACTERICIDE effect On Mycobacterium Leprae.
This publication was launched online in mid-1999, under the title: THE MINOCYCLINE, THE GOOD THE BAD AND THE UGLY. This medicine has been discovered beneficial properties in diseases for which was not created or launched to the market, such is the case of LEPROSY, which describes its BACTERICIDE effect On Mycobacterium Leprae.
Mainly this drug has been, was and is used for acne treatment. But
little Soon the range of its use was extended.
Today I bring you this update, to draw the attention of all readers in the sense that this "OLD" medicine today is described anti-inflammatory and NEUROPROTECTIVE properties in neurological diseases, among Which highlight ALZHEIMER'S DISEASE and SCHIZOPHRENIA. (References 31-53)
Today I bring you this update, to draw the attention of all readers in the sense that this "OLD" medicine today is described anti-inflammatory and NEUROPROTECTIVE properties in neurological diseases, among Which highlight ALZHEIMER'S DISEASE and SCHIZOPHRENIA. (References 31-53)
THE GOOD:
==========
This popular medication will have beneficial effects on
disease like:
1.) LEPROSY (MYCOBACTERIUM LEPRAE)
2.) SCLERODERMA.
3.) PEMPHIGUS.
4.) PYODERMA GANGRENOSUM.
5.) CICATRICIAL PEMPHIGOID.
6.) RETICULATED PAPILLOMATOSIS.
7.) LYME DISEASE (ERYTHEMA MIGRANS)
8.) ACNE.
9.) CHLAMYDIAS.
10.) TREPONEMA.
11.) MYCOBATERIUM KANSAII.
12.) PULMONARY NOCARDIOSIS.
12.) BLASTOMYCOSIS.
13.) RHEUMATOID ARTHRITIS.
14.) HEPATIC CYSTS and OTHERS.
The most interesting of the subject on the MINOCYCLINE
is its use in neorological disorders discovering NEUROPROTECTOR
effects. Minocycline has been found to have beneficial effects
on:
- Inflammation.
- Microglial activation.
- Nitric oxide production.
- Apoptotic cell death into the CENTRAL NERVOUS SYSTEM (CNS): and is being used in diseases such as:
1.) ALZHEIMER'S DISEASE.
2.) PARKINSON'S DISEASE
3.) MULTIPLE SCLEROSIS.
4.) BIPOLAR DISORDERS.
5. SCHIZOPHRENIA.
6.) AUTOINMUNE ENCEPHALOMYELITIS.
Who would have thought that this old antibiotic, which has been
on the market for over 40 years, is now being used to treat
diseases like ALZHEIMER'S and SCHIZOPHRENIA?
The big question is: could MINOCYCLINE be used to induce NEUROPROTECTION, or improve the inflammatory state in these neurological disorders, at a minimal dose to avoid side effects? The only way to know is through further research.
It would also be interesting to know what level of neuroprotection developed in patients who took MINOCYCLINE long-term for acne treatment.
The big question is: could MINOCYCLINE be used to induce NEUROPROTECTION, or improve the inflammatory state in these neurological disorders, at a minimal dose to avoid side effects? The only way to know is through further research.
It would also be interesting to know what level of neuroprotection developed in patients who took MINOCYCLINE long-term for acne treatment.
THE BAD:
==========
As all medicines MINOCYCLINE have their adverse effects, Among them:
1.)
AUTOIMMUNE HEPATITIS.
2.) LUPUS-LIKE SYNDROME IN PATIENTS TREATED FOR ACNE.
3.) EOSINOPHILIC PNEUMONIA.
4.) SYSTEMIC LUPUS ERYTHEMATOSUS.
4.) HYPERSENSITIVITY REACTIONS.
5.) SERUM SICKNESS-LIKE SYNDROME (URTICARIA, FEVER, LYMPHADENOPATHY, AND JOINT PAIN).
6.) POTASSIUM LOSS (RED BLOOD CELLS).
2.) LUPUS-LIKE SYNDROME IN PATIENTS TREATED FOR ACNE.
3.) EOSINOPHILIC PNEUMONIA.
4.) SYSTEMIC LUPUS ERYTHEMATOSUS.
4.) HYPERSENSITIVITY REACTIONS.
5.) SERUM SICKNESS-LIKE SYNDROME (URTICARIA, FEVER, LYMPHADENOPATHY, AND JOINT PAIN).
6.) POTASSIUM LOSS (RED BLOOD CELLS).
THE UGLY:
==========
1.) HYPERPIGMANTATION: This is one of the most frequent side
effects of minocycline use, and has been reported in the gums, bones,
face, and thyroid.
2.) INDUCTION OF AUTOANTIBODIES: (in cases of psoriasis)
3.) HYPERPIGMENTED OSTEOMA CUTIS: (post-acne treatment)
4.) NODULAR HYPERPLASIA: (thyroid)
2.) INDUCTION OF AUTOANTIBODIES: (in cases of psoriasis)
3.) HYPERPIGMENTED OSTEOMA CUTIS: (post-acne treatment)
4.) NODULAR HYPERPLASIA: (thyroid)
The most remarkable aspect of this publication is the discovery
of properties of a
"LONG-FORGOTTEN" drug in
difficult-to-treat diseases such as LEPROSY,
ALZHEIMER'S, and SCHIZOPHRENIA.
A TYPICAL example of this occurred 40 years later, with IVERMECTIN
and HYDROXYCHLOROQUINE, ANTIPARASITICS drugs,
which were found to have an ANTIVIRAL effect, specifically against
the SARS-CoV-2 virus.
This illustrates how a drug synthesized for a specific disease can LATER be found to have other positive effects in other diseases. Examples include:
1.) SILDENAFIL (Viagra): Studied and tested as an antihypertensive, it proved successful in treating erectile dysfunction, and its molecule was later improved (vardenafil and tadalafil).
2.) MINOXIDIL: also studied as an HYPOTENSIVE, trial patients presented with TOTAL HYPERVILLOUSNESS on the face: this led to its use for HAIR LOSS or ALOPECIA.
3.) FINASTERIDE: invented for the treatment of BENIGN PROSTATIC HYPERPLASIA (BPH); it was discovered that it prevented hair loss: this led to the development of PROPECIA, and in November 2024, the TOPICAL version, under the name FINASTOPIC, was launched by the ISDIN laboratory (Spain).
4.) IVERMECTIN: Invented in the 1970s as an antiparasitic, and winner of the Nobel Prize in 2015. It was subsequently used in the treatment of COVID-19 in 2020.
5.) THALIDOMIDE: Launched in 1957 as a medication for nausea and anxiety in pregnant women, with significant TERATOGENIC effects (was this known?). It caused a generation of children "MUTILATED" by an effect called PHOCOMELIA, and was discontinued in 1961. But in 1998, it was relaunched due to its beneficial effects on:
- LEPROSY (Reversal Reaction).
- Various types of CANCER.
- ERYTHEMA NODOSUM.
- MULTIPLE MYELOMA.
- BECETH'S DISEASE.
- RECURRENT APHTHOUS STOMATITIS, and others.
Therefore, this publication (now updated), when I launched it online under the aforementioned title: MINOCYCLINE, THE GOOD, THE BAD, AND THE UGLY, was a complete success, to the point that it was published in the CHILEAN JOURNAL OF DERMATOLOGY... Today, this antibiotic continues to show NEW positive properties.
This illustrates how a drug synthesized for a specific disease can LATER be found to have other positive effects in other diseases. Examples include:
1.) SILDENAFIL (Viagra): Studied and tested as an antihypertensive, it proved successful in treating erectile dysfunction, and its molecule was later improved (vardenafil and tadalafil).
2.) MINOXIDIL: also studied as an HYPOTENSIVE, trial patients presented with TOTAL HYPERVILLOUSNESS on the face: this led to its use for HAIR LOSS or ALOPECIA.
3.) FINASTERIDE: invented for the treatment of BENIGN PROSTATIC HYPERPLASIA (BPH); it was discovered that it prevented hair loss: this led to the development of PROPECIA, and in November 2024, the TOPICAL version, under the name FINASTOPIC, was launched by the ISDIN laboratory (Spain).
4.) IVERMECTIN: Invented in the 1970s as an antiparasitic, and winner of the Nobel Prize in 2015. It was subsequently used in the treatment of COVID-19 in 2020.
"THE FDA DIS NOT APPROVE IT", but there are already studies that demonstrate that it IS effective. However, Big Pharma doesn't want this to be known; but to avoid conflicts of interest: TODAY IT IS NOT APPROVED for use against SARS-CoV-2."
5.) THALIDOMIDE: Launched in 1957 as a medication for nausea and anxiety in pregnant women, with significant TERATOGENIC effects (was this known?). It caused a generation of children "MUTILATED" by an effect called PHOCOMELIA, and was discontinued in 1961. But in 1998, it was relaunched due to its beneficial effects on:
- LEPROSY (Reversal Reaction).
- Various types of CANCER.
- ERYTHEMA NODOSUM.
- MULTIPLE MYELOMA.
- BECETH'S DISEASE.
- RECURRENT APHTHOUS STOMATITIS, and others.
Therefore, this publication (now updated), when I launched it online under the aforementioned title: MINOCYCLINE, THE GOOD, THE BAD, AND THE UGLY, was a complete success, to the point that it was published in the CHILEAN JOURNAL OF DERMATOLOGY... Today, this antibiotic continues to show NEW positive properties.
Today, MINOCYCLINE is FDA-approved for the treatment of acne, but NOT for the treatment of NEUROLOGICAL conditions; in these cases, it is used as a "repurposed" drug.
The original publication of this article can be found at this link:
MINOCYCLINE, THE GOOD, THE BAD AND THE UGLY.
The facts in these 81 references !!
greetings to all !!!
Dr. Jose Lapenta.
Dr. Jose M. Lapenta.
Dr. Jose M. Lapenta.
====================================================================== REFERENCIAS BIBLIOGRÁFICAS / BIBLIOGRAPHICAL REFERENCES
====================================================================== ====================================================================== ()()()()()()()()()()()()LO BUENO () THE GOOD ()()()()()()()()()()()()()()
=========================================================================
A.- Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis (2023).
D.- Ameliorating Alzheimer's-like Pathology by Minocycline via
Inhibiting Cdk5/p25 Signaling (2022).
F.- Leprosy reactions: New knowledge on pathophysiology, diagnosis,
treatment and prevention (2025).
=========================================================================
1.) Superior antibacterial action and reduced incidence of
bacterial
resistance in minocycline compared to tetracycline-treated acne patients.
2.) Tetracycline-resistant propionibacteria from acne patients are
cross-resistant to doxycycline, but sensitive to minocycline.
3.) Research letters : Minocycline in early diffuse scleroderma
4.) Minocycline in lepromatous leprosy.
5.) Efficacy of minocycline in single dose and at 100 mg twice daily for
lepromatous leprosy.
6.) Field trial on efficacy of supervised monthly dose of 600 mg rifampin,
400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first
results.
7.) Bactericidal activity of a single-dose combination of ofloxacin plus
minocycline, with or without rifampin, against Mycobacterium leprae in mice
and in lepromatous patients.
8.) Efficacy of single dose multidrug therapy for the treatment of
single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group.
9.) Bactericidal activity of single dose of clarithromycin plus
minocycline, with or without ofloxacin, against Mycobacterium leprae in
patients.
10.) WHO Expert Committee on Leprosy.
11.) Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy.
12.) Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy.
13.) Minocycline is a useful adjuvant therapy for pemphigus.
14.) Confluent and reticulated papillomatosis: response to minocycline.
15.) Minocycline treatment for confluent and reticulated papillomatosis.
16.) No detection of Borrelia burgdorferi-specific DNA in erythema migrans lesions after minocycline treatment.
17.) Minimizing cicatricial pemphigoid orodynia with minocycline.
18.) Response of atypical bullous pyoderma gangrenosum to oral minocycline
hydrochloride and topical steroids.
19.) Blastomycosis-like pyoderma--report of a case responsive to combination therapy utilizing minocycline and carbon dioxide laser debridement.
20.) A sporotrichoid-like Mycobacterium kansasii infection of the skin treated with minocycline hydrochloride.
21.) Primary lymphocutaneous nocardiosis due to Nocardia otitidiscaviarum:
the first case report from Japan.
22.) Minocycline treatment of pulmonary nocardiosis.
23.) Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group [see comments]
24.) Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats.
25.) Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection.
26.) The role of minocycline in the treatment of intracranial 9L glioma.
27.) Evaluation of the long-term efficacy and safety of locally-applied minocycline in adult periodontitis patients.
28.) Clinical and microbiological effects of minocycline-loaded, microcapsules in adult periodontitis.
29.) The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin.
30.) Symptomatic hepatic cysts: treatment with single-shot injection of minocycline hydrochloride
resistance in minocycline compared to tetracycline-treated acne patients.
2.) Tetracycline-resistant propionibacteria from acne patients are
cross-resistant to doxycycline, but sensitive to minocycline.
3.) Research letters : Minocycline in early diffuse scleroderma
4.) Minocycline in lepromatous leprosy.
5.) Efficacy of minocycline in single dose and at 100 mg twice daily for
lepromatous leprosy.
6.) Field trial on efficacy of supervised monthly dose of 600 mg rifampin,
400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first
results.
7.) Bactericidal activity of a single-dose combination of ofloxacin plus
minocycline, with or without rifampin, against Mycobacterium leprae in mice
and in lepromatous patients.
8.) Efficacy of single dose multidrug therapy for the treatment of
single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group.
9.) Bactericidal activity of single dose of clarithromycin plus
minocycline, with or without ofloxacin, against Mycobacterium leprae in
patients.
10.) WHO Expert Committee on Leprosy.
11.) Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy.
12.) Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy.
13.) Minocycline is a useful adjuvant therapy for pemphigus.
14.) Confluent and reticulated papillomatosis: response to minocycline.
15.) Minocycline treatment for confluent and reticulated papillomatosis.
16.) No detection of Borrelia burgdorferi-specific DNA in erythema migrans lesions after minocycline treatment.
17.) Minimizing cicatricial pemphigoid orodynia with minocycline.
18.) Response of atypical bullous pyoderma gangrenosum to oral minocycline
hydrochloride and topical steroids.
19.) Blastomycosis-like pyoderma--report of a case responsive to combination therapy utilizing minocycline and carbon dioxide laser debridement.
20.) A sporotrichoid-like Mycobacterium kansasii infection of the skin treated with minocycline hydrochloride.
21.) Primary lymphocutaneous nocardiosis due to Nocardia otitidiscaviarum:
the first case report from Japan.
22.) Minocycline treatment of pulmonary nocardiosis.
23.) Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group [see comments]
24.) Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats.
25.) Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection.
26.) The role of minocycline in the treatment of intracranial 9L glioma.
27.) Evaluation of the long-term efficacy and safety of locally-applied minocycline in adult periodontitis patients.
28.) Clinical and microbiological effects of minocycline-loaded, microcapsules in adult periodontitis.
29.) The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin.
30.) Symptomatic hepatic cysts: treatment with single-shot injection of minocycline hydrochloride
31.) Systematic review and meta-analysis of the efficacy and safety
of minocycline in schizophrenia.
32.) Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials.
33.) Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial.
34.) Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial.
35.) Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis.
36.) Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
37.) The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease.
38.) Discovering new treatments for Alzheimer's disease by repurposing approved medications.
39.) Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder.
40.) Anti-apoptotic and anti-oxidative mechanisms of minocycline against sphingomyelinase/ceramide neurotoxicity: implication in Alzheimer's disease and cerebral ischemia.
41.) Clinical potential of minocycline for schizophrenia.
42.) The potential of minocycline for neuroprotection in human neurologic disease.
43.) Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis.
44.) The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi.
45.)[Minocycline].
46.) Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models.
47.) Minocycline and neurodegenerative diseases.
48.) Minocycline attenuates Aβ oligomers-induced pro-inflammatory phenotype in primary microglia while enhancing Aβ fibrils phagocytosis.
49) Discovering new treatments for Alzheimer's disease by repurposing approved medications.
50.) Anti-apoptotic and anti-oxidative mechanisms of minocycline against sphingomyelinase/ceramide neurotoxicity: implication in Alzheimer's disease and cerebral ischemia.
51.) Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology.
52.) Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation.
53.) Minocycline may be useful to prevent/treat postoperative cognitive decline in elderly patients.
32.) Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials.
33.) Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial.
34.) Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial.
35.) Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis.
36.) Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
37.) The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease.
38.) Discovering new treatments for Alzheimer's disease by repurposing approved medications.
39.) Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder.
40.) Anti-apoptotic and anti-oxidative mechanisms of minocycline against sphingomyelinase/ceramide neurotoxicity: implication in Alzheimer's disease and cerebral ischemia.
41.) Clinical potential of minocycline for schizophrenia.
42.) The potential of minocycline for neuroprotection in human neurologic disease.
43.) Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis.
44.) The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi.
45.)[Minocycline].
46.) Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models.
47.) Minocycline and neurodegenerative diseases.
48.) Minocycline attenuates Aβ oligomers-induced pro-inflammatory phenotype in primary microglia while enhancing Aβ fibrils phagocytosis.
49) Discovering new treatments for Alzheimer's disease by repurposing approved medications.
50.) Anti-apoptotic and anti-oxidative mechanisms of minocycline against sphingomyelinase/ceramide neurotoxicity: implication in Alzheimer's disease and cerebral ischemia.
51.) Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology.
52.) Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation.
53.) Minocycline may be useful to prevent/treat postoperative cognitive decline in elderly patients.
======================================================================
()()()(()()()()()()()()( LO MALO () THE BAD ()()()()()()()()()()()()()()
======================================================================
1.) Minocycline induced autoimmune hepatitis and systemic lupus
erythematosus-like syndrome [see comments]
2.) Minocycline and Lupuslike Syndrome in Acne Patients
3.) Minocycline-induced lupus.
4.) Minocycline related lupus.
5.) Acute hepatitis and drug-related lupus induced by minocycline treatment.
6.) Minocycline-induced pneumonitis with bilateral hilar lymphadenopathy
and pleural effusion.
7.) Comparative safety of tetracycline, minocycline, and doxycycline.
8.) Serious adverse reactions induced by minocycline. Report of 13
patients and review of the literature.
9.) [Side effects of minocycline in the treatment of acne vulgaris]
10.) Serious dermatologic reactions in children.
11.) Serum sickness-like syndrome associated with minocycline therapy.
12.) Minocycline-induced loss of potassium from erythrocytes:
identification of a family with an augmented response.
======================================================================
()()()()()()()()()()()()()() LO FEO () THE UGLY ()()()()()()()()()()()()
======================================================================
13.) Minocycline-induced hyperpigmentation in leprosy.
14.) Psoriatic arthritis and minocycline induced autoantibodies.
15.) Minocycline hydrochloride hyperpigmentation complicating treatment of
pyoderma gangrenosum.
16.) Minocycline-induced oral pigmentation.
17.) Nodular hyperplasia, black thyroid, and chronic minocycline ingestion
in a teenager.
18.) Black bones following long-term minocycline treatment.
19.) Pigmented postacne osteoma cutis in a patient treated with
minocycline: report and review of the literature.
20.) ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review.
======================================================================
()()()(()()()()()()()()( LO MALO () THE BAD ()()()()()()()()()()()()()()
======================================================================
1.) Minocycline induced autoimmune hepatitis and systemic lupus
erythematosus-like syndrome [see comments]
2.) Minocycline and Lupuslike Syndrome in Acne Patients
3.) Minocycline-induced lupus.
4.) Minocycline related lupus.
5.) Acute hepatitis and drug-related lupus induced by minocycline treatment.
6.) Minocycline-induced pneumonitis with bilateral hilar lymphadenopathy
and pleural effusion.
7.) Comparative safety of tetracycline, minocycline, and doxycycline.
8.) Serious adverse reactions induced by minocycline. Report of 13
patients and review of the literature.
9.) [Side effects of minocycline in the treatment of acne vulgaris]
10.) Serious dermatologic reactions in children.
11.) Serum sickness-like syndrome associated with minocycline therapy.
12.) Minocycline-induced loss of potassium from erythrocytes:
identification of a family with an augmented response.
======================================================================
()()()()()()()()()()()()()() LO FEO () THE UGLY ()()()()()()()()()()()()
======================================================================
13.) Minocycline-induced hyperpigmentation in leprosy.
14.) Psoriatic arthritis and minocycline induced autoantibodies.
15.) Minocycline hydrochloride hyperpigmentation complicating treatment of
pyoderma gangrenosum.
16.) Minocycline-induced oral pigmentation.
17.) Nodular hyperplasia, black thyroid, and chronic minocycline ingestion
in a teenager.
18.) Black bones following long-term minocycline treatment.
19.) Pigmented postacne osteoma cutis in a patient treated with
minocycline: report and review of the literature.
20.) ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review.
======================================================================
